Medicare Enrolled
Dr. Jeremy Jones, MD
Hematology & Oncology · Jacksonville, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Jones from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jones? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jones
Dr. Jeremy Jones is a hematology & oncology in Jacksonville, FL, with 15 years in practice. Based on federal Medicare data, Dr. Jones performed 137,072 Medicare services across 3,458 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jones received a total of $10,699 from 48 pharmaceutical and/or device companies across 334 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jones is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years in practice▲ Top 4% volume in FL$ $10,699 industry payments
Medicare Practice Summary
Medicare Utilization ↗137,072
Medicare services
Top 4% in FL for hematology & oncology
3,458
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,138 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 21,202 | $40 | $190 |
| Iron infusion (Feraheme) | 16,830 | $0 | $2 |
| Nivolumab injection (Opdivo) | 16,660 | $24 | $114 |
| Filgrastim injection (Nivestym) for white blood cells | 12,960 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) | 10,350 | $0 | $1 |
| Daratumumab injection (Darzalex) | 8,460 | $38 | $191 |
| Darbepoetin injection (Aranesp) for anemia | 6,430 | $2 | $11 |
| Paclitaxel chemotherapy injection | 5,484 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 4,800 | $18 | $90 |
| Oxaliplatin chemotherapy injection | 4,600 | $0 | $1 |
| Injection, paclitaxel protein-bound particles, 1 mg | 4,200 | $10 | $51 |
| Dexamethasone injection (steroid) | 2,598 | $0 | $4 |
| Immune globulin infusion (Gammagard) | 2,340 | $36 | $137 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 2,290 | $21 | $181 |
| Anti-nausea injection (ondansetron/Zofran) | 2,080 | $0 | $5 |
| Injection, atezolizumab, 10 mg | 1,776 | $64 | $322 |
| Injection, docetaxel, 1 mg | 1,770 | $1 | $5 |
| Injection, carfilzomib, 1 mg | 1,740 | $34 | $173 |
| Injection, bortezomib, 0.1 mg | 1,120 | $4 | $9 |
| Injection, atropine sulfate, 0.01 mg | 1,115 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 910 | $22 | $194 |
| Injection of additional new drug or substance into vein | 708 | $12 | $216 |
| Anti-nausea injection (Aloxi/palonosetron) | 600 | $1 | $8 |
| Administration of chemotherapy into vein, 1 hour or less | 468 | $100 | $869 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 361 | $3 | $37 |
| Injection, fluorouracil, 500 mg | 328 | $2 | $28 |
| Injection, fulvestrant, 25 mg | 320 | $8 | $48 |
| Injection, leucovorin calcium, per 50 mg | 310 | $3 | $20 |
| Injection, irinotecan, 20 mg | 301 | $2 | $22 |
| Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | 252 | $82 | $459 |
| Injection, carboplatin, 50 mg | 236 | $2 | $31 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 231 | $132 | $501 |
| Injection, potassium chloride, per 2 meq | 225 | $0 | $15 |
| Collection of blood sample from implanted device | 217 | $20 | $135 |
| Office visit, established patient (30-39 min) | 215 | $96 | $450 |
| Infusion into a vein for hydration, each additional hour | 185 | $10 | $114 |
| Infusion, normal saline solution , 1000 cc | 185 | $2 | $82 |
| Drug injection, under skin or into muscle | 180 | $11 | $102 |
| Injection, magnesium sulfate, per 500 mg | 170 | $1 | $17 |
| Injection, cisplatin, powder or solution, 10 mg | 135 | $2 | $36 |
| Cyclophosphamide, 100 mg | 135 | $15 | $117 |
| Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | 132 | $67 | $633 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 126 | $22 | $233 |
| Administration of additional new drug or substance into vein, 1 hour or less | 126 | $49 | $446 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 109 | $48 | $426 |
| Administration of chemotherapy into vein, each additional hour | 107 | $22 | $212 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 104 | $56 | $352 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 101 | $26 | $200 |
| Injection, diphenhydramine hcl, up to 50 mg | 99 | $1 | $37 |
| Injection, zoledronic acid, 1 mg | 80 | $7 | $46 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 79 | $16 | $154 |
| Office visit, established patient, complex (40-54 min) | 66 | $132 | $604 |
| Infusion into a vein for hydration, 31-60 minutes | 62 | $25 | $345 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 62 | $1 | $74 |
| New patient office visit, complex (60-74 min) | 60 | $167 | $891 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 53 | $133 | $993 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 49 | $15 | $143 |
| Injection of drug or substance into vein | 39 | $28 | $600 |
| Administration of additional new drug or substance into vein using push technique | 34 | $43 | $370 |
| Infusion, normal saline solution, 250 cc | 32 | $1 | $48 |
| Injection, lorazepam, 2 mg | 21 | $1 | $73 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $17 | $96 |
| Administration of chemotherapy into vein using push technique | 18 | $78 | $640 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 17 | $4 | $68 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
14.7% high complexity
84.5% medium
0.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,699
Total received (2018-2024)
Avg $1,528/year across 7 years
Top 35% in FL for hematology & oncology
48
Companies
334
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,135 (48.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,953 (46.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$611 (5.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$253
2023$549
2022$169
2021$143
2020$71
2019$6,125
2018$3,389
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$2,217
AstraZeneca Pharmaceuticals LP
$1,924
Bayer HealthCare Pharmaceuticals Inc.
$1,517
Amgen Inc.
$748
Novartis Pharmaceuticals Corporation
$578
PFIZER INC.
$312
Merck Sharp & Dohme Corporation
$252
Janssen Biotech, Inc.
$250
Incyte Corporation
$222
Bayer Healthcare Pharmaceuticals Inc.
$216
GENZYME CORPORATION
$212
Ipsen Biopharmaceuticals, Inc
$211
Genentech, Inc.
$197
Genentech USA, Inc.
$174
Celgene Corporation
$152
Astellas Pharma US Inc
$142
Exelixis Inc.
$122
Takeda Pharmaceuticals U.S.A., Inc.
$108
Seagen Inc.
$95
TESARO, Inc.
$81
Stryker Corporation
$75
Boehringer Ingelheim Pharmaceuticals, Inc.
$71
Kyowa Kirin, Inc.
$69
Lilly USA, LLC
$62
Alexion Pharmaceuticals, Inc.
$57
Eisai Inc.
$56
AMAG Pharmaceuticals, Inc.
$41
Merck Sharp & Dohme LLC
$40
Agios Pharmaceuticals, Inc.
$40
Daiichi Sankyo Inc.
$38
EISAI INC.
$34
Gilead Sciences, Inc.
$33
Janssen Pharmaceuticals, Inc
$33
AbbVie, Inc.
$31
Pharmacyclics LLC, An AbbVie Company
$29
ARRAY BIOPHARMA INC
$29
Taiho Oncology, Inc.
$28
TOLMAR Pharmaceuticals, Inc.
$28
Tempus AI, Inc
$28
Foundation Medicine, Inc.
$23
MEDIVATION FIELD SOLUTIONS LLC
$18
Array BioPharma Inc.
$17
Seattle Genetics, Inc.
$17
Regeneron Healthcare Solutions, Inc.
$15
TerSera Therapeutics LLC
$15
Clovis Oncology, Inc.
$15
Spectrum Pharmaceuticals Inc.
$13
INSYS Therapeutics Inc
$12
Top 3 companies account for 52.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · Abraxane · Alecensa · Aliqopa · Avastin · BOSULIF · Braftovi · CALQUENCE · CHANTIX · CYRAMZA · Cabometyx · DARZALEX · ELIGARD · ELIQUIS · ELITEK · ERLEADA · Erleada · FARESTON · FASLODEX · FERAHEME · FOUNDATIONONE · Folotyn · GAMMA · GAZYVA · GILOTRIF · Halaven · IBRANCE · IDHIFA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MVASI · MYLOTARG · NINLARO · Neulasta · Nplate · OPDIVO · Onivyde · PROMACTA · Perjeta · Pomalyst · Revlimid · Rubraca · SANCUSO · SANDOSTATIN · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · Tarceva · ULTOMIRIS · VENCLEXTA · VOTRIENT · Venclexta · Vitrakvi · XALKORI · XARELTO · XTANDI · Xofigo · ZEJULA · ZOLADEX · ZYTIGA · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (48%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $8 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
104
Per 100K population
10.3
County median income
$68,447
Nearest hospital
MAYO CLINIC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Jones is a mixed practice specialist, with above-average Medicare volume (top 4% in FL), and mixed engagement industry engagement, with 15 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Jones experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Jones performed 21,202 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jones receive payments from pharmaceutical companies?
Yes. Dr. Jones received a total of $10,699 from 48 companies across 334 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jones's costs compare to other hematology & oncologys in Jacksonville?
Dr. Jones's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jones) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Jacksonville
Browse hematology & oncologys in Jacksonville ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology